Zhejiang Jing Pharmaceutical: Net loss of 163 million yuan in 2025

2026-03-29 12:52:54

People’s Finance News, March 27 - Zai Jing Pharmaceutical (688266) disclosed its annual report on March 27, reporting an operating income of 810 million yuan for 2025, a year-on-year increase of 52.07%; the net profit attributable to shareholders was a loss of 163 million yuan, compared to a loss of 137 million yuan during the same period last year. The loss during the reporting period increased compared to the previous year, mainly due to the growth in marketing expenses for the promotion of recombinant thrombin and gilteritinib tablets, changes in the sales expense structure leading to an overall increase in sales expenses, and also because the research and development expenses increased compared to last year due to the different specific research and development stages of new drug projects.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes